Literature DB >> 33503328

Clinicopathologic and MRI features of combined hepatocellular-cholangiocarcinoma in patients with or without cirrhosis.

Jongjin Yoon1, Jeong A Hwang2, Sunyoung Lee1, Ji E Lee2,3, Sang Y Ha4, Young N Park5.   

Abstract

BACKGROUND AND AIMS: Differences in combined hepatocellular-cholangiocarcinomas (cHCC-CCAs) arising in high-risk patients with or without liver cirrhosis have not been elucidated. This study aimed to compare the clinicopathologic and imaging characteristics of cHCC-CCAs in patients with or without cirrhosis and to determine the prognostic factors for recurrence-free survival (RFS) after curative resections of single cHCC-CCAs.
METHODS: This retrospective study included 113 patients with surgically resected single cHCC-CCAs who underwent preoperative magnetic resonance imaging from January 2008 to December 2019 at two tertiary referral centres. Clinical, pathologic and imaging features of tumours were compared in high-risk patients with or without cirrhosis. Imaging features were assessed using the Liver Imaging Reporting and Data System (LI-RADS) version 2018. RFS and associated factors were evaluated using Cox proportional hazards regression analysis, Kaplan-Meier analysis and log-rank test.
RESULTS: cHCC-CCAs arising from cirrhotic livers had a smaller mean tumour size (2.9 cm vs. 4.5 cm; P < .001) and were more frequently categorized as LR-5 or 4 (41.2% vs. 20.0%; P = .024) than those arising from non-cirrhotic livers. In multivariable analysis, a tumour size of > 3 cm (hazard ratio [HR], 2.081; 95% confidence interval [CI], 1.180-3.668; P = .011) and the LR-M category (HR, 2.302; 95% CI, 1.198-4.424; P = .012) were independent predictors associated with worse RFS.
CONCLUSIONS: The tumour size and distribution of LI-RADS categories of cHCC-CCAs differed in high-risk patients with or without cirrhosis. And LR-M category was a worse prognosis predictor after curative resections than LR-5 or 4 category.
© 2021 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  cirrhosis; combined hepatocellular-cholangiocarcinoma; magnetic resonance imaging; prognosis

Mesh:

Substances:

Year:  2021        PMID: 33503328     DOI: 10.1111/liv.14798

Source DB:  PubMed          Journal:  Liver Int        ISSN: 1478-3223            Impact factor:   5.828


  2 in total

1.  Diagnostic Performance of LI-RADS Version 2018 for Primary Liver Cancer in Patients With Liver Cirrhosis on Enhanced MRI.

Authors:  Xinai Liu; Xiaoyan Ni; Yubo Li; Chun Yang; Yi Wang; Chunzheng Ma; Changwu Zhou; Xin Lu
Journal:  Front Oncol       Date:  2022-07-01       Impact factor: 5.738

2.  Morbidity, Prognostic Factors, and Competing Risk Nomogram for Combined Hepatocellular-Cholangiocarcinoma.

Authors:  Xiaoyuan Chen; Yiwei Lu; Xiaoli Shi; Xuejiao Chen; Dawei Rong; Guoyong Han; Long Zhang; Chuangye Ni; Jie Zhao; Yun Gao; Xuehao Wang
Journal:  J Oncol       Date:  2021-12-10       Impact factor: 4.375

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.